1d11 (tgf-β1 neutralizing antibody (R&D Systems)
Structured Review
1d11 (Tgf β1 Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1d11+(tgf-%CE%B21+neutralizing+antibody/tgf+%CE%B21/us12049475-694-6-10
Average 90 stars, based on 1 article reviews
Images
Related Articles
other:Article Title: Bisphosphonate drug conjugates Article Snippet: An alginate bead containing 0.1 μg Article Title: Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells Article Snippet: Bioactivity-neutralizing Blocking Assay:Article Title: Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis. Article Snippet: .. Cells were treated with high glucose (30 mM, Sigma, G7201) or TGF-β1 (5 ng/mL, R&D Systems) with or without the following: csGRP78/α2M* inhibiting peptide (previously shown to block high glucose responses in mesangial cells, CLIGRTWNDPSVQQDIKFL) (4) or control scrambled peptide (GTNKSQDLWIPQLRDVFI) (both at 100 nM, generated in-house); csGRP78 neutralizing antibody, which blocks csGRP78/α2M* interaction (C38, 10 μg, generated in-house) (4, 14); α2M* neutralizing mouse monoclonal antibody, clone 16-11-17, which binds specifically to the α2M receptor binding domain (Fα2M, previously described in ref. 48; 10 μg, generated in-house); integrin β1 neutralizing antibody (10 μg, BioLegend, 303036); Article Title: Inhibition of cell surface GRP78 and activated α 2M interaction attenuates kidney fibrosis Article Snippet: .. Cells were treated with high glucose (30 mM, Sigma, G7201) or TGF-β1 (5 ng/mL, R&D Systems) with or without the following: csGRP78/α2M* inhibiting peptide (previously shown to block high glucose responses in mesangial cells, CLIGRTWNDPSVQQDIKFL) ( ) or control scrambled peptide (GTNKSQDLWIPQLRDVFI) (both at 100 nM, generated in-house); csGRP78 neutralizing antibody, which blocks csGRP78/α2M* interaction (C38, 10 μg, generated in-house) ( , ); α2M* neutralizing mouse monoclonal antibody, clone 16-11-17, which binds specifically to the α2M receptor binding domain (Fα2M, previously described in ref. ; 10 μg, generated in-house); integrin β 1 neutralizing antibody (10 μg, BioLegend, 303036); Article Title: Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1. Article Snippet: Selective inhibition of the RGD (Arg-Gly-Asp) integrin αvβ1 has been recently identified as an attractive therapeutic approach for the treatment of liver fibrosis given its function, target expression, and safety profile.. Our identification of a non-RGD small molecule lead followed by focused, systematic changes to the core structure utilizing a crystal structure, in silico modeling, and a tractable synthetic approach resulted in the identification of a potent small molecule exhibiting a remarkable affinity for αvβ1 relative to several other integrin isoforms measured.. Azabenzimidazolone 25 demonstrated antifibrotic efficacy in an in vivo rat liver fibrosis model and represents a tool compound capable of further exploring the biological consequences of selective αvβ1 inhibition. Control:Article Title: Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis. Article Snippet: .. Cells were treated with high glucose (30 mM, Sigma, G7201) or TGF-β1 (5 ng/mL, R&D Systems) with or without the following: csGRP78/α2M* inhibiting peptide (previously shown to block high glucose responses in mesangial cells, CLIGRTWNDPSVQQDIKFL) (4) or control scrambled peptide (GTNKSQDLWIPQLRDVFI) (both at 100 nM, generated in-house); csGRP78 neutralizing antibody, which blocks csGRP78/α2M* interaction (C38, 10 μg, generated in-house) (4, 14); α2M* neutralizing mouse monoclonal antibody, clone 16-11-17, which binds specifically to the α2M receptor binding domain (Fα2M, previously described in ref. 48; 10 μg, generated in-house); integrin β1 neutralizing antibody (10 μg, BioLegend, 303036); Article Title: Inhibition of cell surface GRP78 and activated α 2M interaction attenuates kidney fibrosis Article Snippet: .. Cells were treated with high glucose (30 mM, Sigma, G7201) or TGF-β1 (5 ng/mL, R&D Systems) with or without the following: csGRP78/α2M* inhibiting peptide (previously shown to block high glucose responses in mesangial cells, CLIGRTWNDPSVQQDIKFL) ( ) or control scrambled peptide (GTNKSQDLWIPQLRDVFI) (both at 100 nM, generated in-house); csGRP78 neutralizing antibody, which blocks csGRP78/α2M* interaction (C38, 10 μg, generated in-house) ( , ); α2M* neutralizing mouse monoclonal antibody, clone 16-11-17, which binds specifically to the α2M receptor binding domain (Fα2M, previously described in ref. ; 10 μg, generated in-house); integrin β 1 neutralizing antibody (10 μg, BioLegend, 303036); Generated:Article Title: Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis. Article Snippet: .. Cells were treated with high glucose (30 mM, Sigma, G7201) or TGF-β1 (5 ng/mL, R&D Systems) with or without the following: csGRP78/α2M* inhibiting peptide (previously shown to block high glucose responses in mesangial cells, CLIGRTWNDPSVQQDIKFL) (4) or control scrambled peptide (GTNKSQDLWIPQLRDVFI) (both at 100 nM, generated in-house); csGRP78 neutralizing antibody, which blocks csGRP78/α2M* interaction (C38, 10 μg, generated in-house) (4, 14); α2M* neutralizing mouse monoclonal antibody, clone 16-11-17, which binds specifically to the α2M receptor binding domain (Fα2M, previously described in ref. 48; 10 μg, generated in-house); integrin β1 neutralizing antibody (10 μg, BioLegend, 303036); Article Title: Inhibition of cell surface GRP78 and activated α 2M interaction attenuates kidney fibrosis Article Snippet: .. Cells were treated with high glucose (30 mM, Sigma, G7201) or TGF-β1 (5 ng/mL, R&D Systems) with or without the following: csGRP78/α2M* inhibiting peptide (previously shown to block high glucose responses in mesangial cells, CLIGRTWNDPSVQQDIKFL) ( ) or control scrambled peptide (GTNKSQDLWIPQLRDVFI) (both at 100 nM, generated in-house); csGRP78 neutralizing antibody, which blocks csGRP78/α2M* interaction (C38, 10 μg, generated in-house) ( , ); α2M* neutralizing mouse monoclonal antibody, clone 16-11-17, which binds specifically to the α2M receptor binding domain (Fα2M, previously described in ref. ; 10 μg, generated in-house); integrin β 1 neutralizing antibody (10 μg, BioLegend, 303036); Binding Assay:Article Title: Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis. Article Snippet: .. Cells were treated with high glucose (30 mM, Sigma, G7201) or TGF-β1 (5 ng/mL, R&D Systems) with or without the following: csGRP78/α2M* inhibiting peptide (previously shown to block high glucose responses in mesangial cells, CLIGRTWNDPSVQQDIKFL) (4) or control scrambled peptide (GTNKSQDLWIPQLRDVFI) (both at 100 nM, generated in-house); csGRP78 neutralizing antibody, which blocks csGRP78/α2M* interaction (C38, 10 μg, generated in-house) (4, 14); α2M* neutralizing mouse monoclonal antibody, clone 16-11-17, which binds specifically to the α2M receptor binding domain (Fα2M, previously described in ref. 48; 10 μg, generated in-house); integrin β1 neutralizing antibody (10 μg, BioLegend, 303036); Article Title: Inhibition of cell surface GRP78 and activated α 2M interaction attenuates kidney fibrosis Article Snippet: .. Cells were treated with high glucose (30 mM, Sigma, G7201) or TGF-β1 (5 ng/mL, R&D Systems) with or without the following: csGRP78/α2M* inhibiting peptide (previously shown to block high glucose responses in mesangial cells, CLIGRTWNDPSVQQDIKFL) ( ) or control scrambled peptide (GTNKSQDLWIPQLRDVFI) (both at 100 nM, generated in-house); csGRP78 neutralizing antibody, which blocks csGRP78/α2M* interaction (C38, 10 μg, generated in-house) ( , ); α2M* neutralizing mouse monoclonal antibody, clone 16-11-17, which binds specifically to the α2M receptor binding domain (Fα2M, previously described in ref. ; 10 μg, generated in-house); integrin β 1 neutralizing antibody (10 μg, BioLegend, 303036); Concentration Assay:Article Title: Splenectomy improves liver fibrosis via tumor necrosis factor superfamily 14 (LIGHT) through the JNK/TGF-β1 signaling pathway Article Snippet: .. The concentration of both the Expressing:Article Title: TGF-β1 promotes expression of fibrosis-related genes through the induction of histone variant H3.3 and histone chaperone HIRA Article Snippet: .. To investigate the expression pathway of histone H3.3 and HIRA in UUO mice, neutralizing Injection:Article Title: TGF-β1 promotes expression of fibrosis-related genes through the induction of histone variant H3.3 and histone chaperone HIRA Article Snippet: .. To investigate the expression pathway of histone H3.3 and HIRA in UUO mice, neutralizing |
Figure S2 . " width="250" height="auto" />
Figure S3 . " width="100%" height="100%">
Figure S4 and and . " width="100%" height="100%">